With Continuous Failure Active Biotech Regains Global Rights for Laquinimod from Teva

 With Continuous Failure Active Biotech Regains Global Rights for Laquinimod from Teva

With Continuous Failure Active Biotech Regains Global Rights for Laquinimod from Teva

Shots:

  • Teva was assessing laquinimod since 2007, globally the drug completed three P-III studies ALLEGRO, BRAVO and CONCERTO in rrMS, P-II study ARPEGGIO in primary progressive MS and single P-II LEGATO-HD trial in Huntington’s Disease(HD)
  • The P-II LEGATO-HD trial in HD fails to meet 1EP@12 mos, additionally in Dec 2017, P-II POC study of laquinimod didn’t meet 1EP and 2EP in Primary Progressive MS
  • Laquinimod a qd PO selective aryl hydrocarbon receptor (AhR), for treatment of MS and HD and is also being studied for Crohn’s disease and Lupus

Click here to read full press release/ article | Ref: Active Biotech | Image: Affarsvarlde

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post